Patents
Literature
7 results about "Barbiturate" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A barbiturate is a drug that acts as a central nervous system depressant, and can therefore produce a wide range of effects, from mild sedation to death. Barbiturates are effective as anxiolytics, hypnotics, and anticonvulsants, but have physical and psychological addiction potential as well as overdose potential among other possible adverse effects. They have largely been replaced by benzodiazepines and nonbenzodiazepines ("Z-drugs") in routine medical practice, particularly in the treatment of anxiety and insomnia, due to the significantly lower risk of addiction and overdose and the lack of an antidote for barbiturate overdose. Despite this, barbiturates are still in use for various purposes: in general anesthesia, epilepsy, treatment of acute migraines or cluster headaches, euthanasia, capital punishment, and assisted suicide.
5-[2,7-diazaspiro[3.5]nonan-7-YL]-5-[4-phenoxyphenyl]hexahydropyrimidine-2,4,6-trione derivatives as MMP9 inhibitors for the treatment of dry eye disease
PCT designated stage expiredWO2025104154A1Organic active ingredientsSenses disorderDiseaseOcular surface disease
The present invention relates to spirocyclic barbiturates of the general formula (I) or a pharmaceutically acceptable salt thereof, as MMP9 inhibitors for the treatment of ocular surface diseases, such as e.g. dry eye disease.
![5-[2,7-diazaspiro[3.5]nonan-7-YL]-5-[4-phenoxyphenyl]hexahydropyrimidine-2,4,6-trione derivatives as MMP9 inhibitors for the treatment of dry eye disease](https://images-eureka.patsnap.com/patent_img/57771d01-3007-4afa-b52d-0be7fe6180a9/EP2024082307_22052025_pf_fp.png "5-[2,7-diazaspiro[3.5]nonan-7-YL]-5-[4-phenoxyphenyl]hexahydropyrimidine-2,4,6-trione derivatives as MMP9 inhibitors for the treatment of dry eye disease")
Owner:F HOFFMANN LA ROCHE & CO AG +1
Glycosyl barbiturates
The present invention relates to a gelling agent comprising a saccharide having general formula (I), in which - Sacc is in pyranose and / or furanose form and represents a monosaccharide or polysaccharide containing up to 20 saccharide units of the L and / or D series, said monosaccharide or polysaccharide having at least one free hydroxyl function, - X1 + is Na + , Li + , K + , + NR 3 R 4 R 5 R 6 , and R 7 -NH3 + R may be the same or different and represent a cation selected from the group consisting of 3 , R 4 , R 5 , and R 6 is (C1~C 20 ) represents an alkyl group, R 7 is (C1~C 20 ) alkyl group, optionally containing at least one unsaturation, said alkyl group optionally containing at least one (C6-C 10 ) substituted with an aryl group, - R 2 represents in particular H or methyl] and compounds having tautomeric forms thereof. JPEG2025502441000016.jpg33170
Owner:CENT NAT DE LA RECH SCI (C N R S)
Methods of treating hypertension by transcranial focused ultrasound
A minimally invasive method of reducing hypertension using focused ultrasound is provided. Upon injection of ultrasound responsive nanodroplets loaded with a therapeutic agent, such as a barbital drug, focused ultrasound is delivered to the noradrenaline producing area, such as the area of grey matter around an aqueduct, thereby locally releasing the therapeutic agent payload from the nanodroplets and achieving a therapeutic reduction of blood pressure. For example, acoustic emissions from vaporized droplets may be employed to infer one or more treatment parameters from a pre-established correlation. For example, plasma hormone content and / or blood pressure changes may be inferred, thereby providing a method of real-time treatment monitoring. The example methods are useful for effecting blood pressure reduction in subjects exhibiting drug-resistant hypertension.
Owner:SUNNYBROOK RES INST
Specific arylidene barbiturate derivative molecules for use as drug candidates in cancer treatment
PendingEP4618960A4Organic chemistryKetone active ingredientsPharmaceutical drugPharmaceutical Substances
The invention relates to the compound shown in Formula I, II, III and IV or pharmaceutically acceptable salt, solvent, hydrate, hydrate salt, polymorph, optical isomer, geometric isomer, enantiomer, diastereomer thereof effective in the treatment of cancer.
Owner:T C ISTANBUL MEDIPOL UNIVERSITESI +1
Transcranial focused ultrasound for hypertension treatment
A minimally invasive method for lowering hypertension using focused ultrasound is provided. Following injection of ultrasound-responsive nanodroplets containing a therapeutic agent (e.g., a barbiturate), focused ultrasound is delivered to norepinephrine-producing regions, such as the periaqueductal gray area, resulting in localized release of the therapeutic payload from the nanodroplets, achieving therapeutic blood pressure reduction. Acoustic emissions from the evaporating droplets can be used to infer one or more therapeutic parameters, for example, based on pre-established correlations. For example, changes in plasma hormone content and / or blood pressure can be inferred, thereby providing a means for real-time treatment monitoring. An exemplary method of the present invention can be used to achieve blood pressure reduction in subjects exhibiting drug-resistant hypertension.
Owner:SUNNYBROOK RES INST
5-[2,7-diazaspiro[3,5]nonane-7-yl]-5-[4-phenoxyphenyl]hexahydropyrimidine-2,4,6-trione derivatives used as MMP9 inhibitors for the treatment of dry eye disease
PendingCN122138962AOrganic active ingredientsSenses disorderOcular surface diseasePharmaceutical medicine
This invention relates to spirocyclic barbiturates of general formula (I) or pharmaceutically acceptable salts thereof as MMP9 inhibitors for the treatment of ocular surface diseases, such as, for example, dry eye disease.
![5-[2,7-diazaspiro[3,5]nonane-7-yl]-5-[4-phenoxyphenyl]hexahydropyrimidine-2,4,6-trione derivatives used as MMP9 inhibitors for the treatment of dry eye disease](https://images-eureka.patsnap.com/patent_img/c0ad7e4f-ba79-490d-b4c6-aea24f6dbafb/CN122138962A.png "5-[2,7-diazaspiro[3,5]nonane-7-yl]-5-[4-phenoxyphenyl]hexahydropyrimidine-2,4,6-trione derivatives used as MMP9 inhibitors for the treatment of dry eye disease")
Owner:F HOFFMANN LA ROCHE & CO AG
Methods for the treatment of hypertension via transcranial-focused-ultrasound
A minimally invasive method for the reduction of hypertension is provided using focused ultrasound. After injection of ultrasound-responsive nanodroplets loaded with a therapeutic agent (e.g. barbiturates), focused ultrasound is delivered to a norepinephrine-producing region, such as the periaqueductal gray region, thereby locally releasing the therapeutic agent payload from the nanodroplets and achieving a therapeutic reduction in blood pressure. Acoustic emissions from vaporizing droplets may be employed, for example, to infer one or more therapeutic parameters based on a pre-established correlation. For example, plasma hormone content and / or the change in blood pressure may be inferred, thereby providing a means of real-time treatment monitoring. The present example methods may be employed to achieve a reduction in blood pressure for subjects exhibiting drug-resistant hypertension.
Owner:SUNNYBROOK RES INST